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Abstract 
Objectives:  Health Technology Assessment (HTA) agencies produce recommendations that guide public funding of 
pharmaceuticals, based on various criteria. We explored factors that may contribute to explaining differences in 
coverage decisions by the National Institute for Health and Care Excellence (NICE) in England and Wales, the 
Scottish Medicines Consortium (SMC), the Dutch College voor Zorgverzekeringen (CVZ), and the French Haute 
Autorité de Santé (HAS). 
Methods:  A dataset of 977 HTA decisions made in 2004-2009 was created.  A three-category outcome variable 
was used (decision to ‘recommend’, ‘restrict’ or ‘not recommend’ a technology).  Multivariate analyses explored 
impacts of clinical, economic, process and socio-economic variables in their decision-making. 
Results:  Relative to the CVZ and adjusting for a range of confounders, technologies were more likely to be 
recommended by NICE and HAS, and restricted or not-recommended by the SMC.  Recommendation was 
significantly associated (p≤0.10) with several variables:  strength of clinical evidence (number of trials, use of active 
comparator-arm, demonstration of clinical superiority) orphan status and indication for cancer.  Simultaneous 
assessment of multiple rather than single pharmaceuticals was associated with increased probability of restriction.  
Conclusions:  In this European multi-HTA study, appraisal outcomes differed significantly across HTA bodies.  A 
range of evidence and non-evidence factors were associated with HTA decisions, confirming the value of 
comprehensive, multivariate analyses.   Nevertheless, a large proportion of variance in HTA decisions remained 
unexplained, suggesting that greater transparency of decision-making is needed, along with associated further 
research.  
 
 
Word count: 234 
 
 
2 
 
Key points: 
1. European HTA agencies included in this analysis significantly differed in their decision-making, after 
adjusting for a range of factors including the scoping and decision-making process, evidence considered, 
and socio-economic differences 
2. The strength of the evidence demonstrating the clinical value of the pharmaceutical, together with the 
therapeutic area which it targets, have a significant role in HTA decisions 
3. ‘Untangling’ the complexity of payer decision-making was limited given that multivariate analyses could 
only explain between 13% and 30% of the observed variability in decision-making, despite taking into 
account a wide range of variables 
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1. Introduction 
The health technology assessment (HTA) decision-making process is prominent in several European countries, 
and advises healthcare systems on the appropriate use of pharmaceuticals (among other technologies) and 
whether they should be recommended for public funding. HTA decisions have an impact on clinicians and 
patients by defining to whom a medicine can be made available, for how long, at what price and under what 
circumstances or conditions.  Thus HTA decisions represent a key point within the complex decision-making 
process that governs funding and access for pharmaceuticals in some countries.   
Because HTA decisions have a significant impact on patient care, transparency around HTA decision-making is 
highly important. For example, the European Commission (1) has launched an up-date of the EU Transparency 
Directive (89/105/EEC) to further emphasize this notion.  The proposed amendment from the European 
Commission now includes direct reference to the concept of transparency and proposes that determination of 
price and access requires “transparent, objective and verifiable criteria” [p.11]. 
It is within this context that we examine the impact of a range of evidence, process and socio-economic factors 
on HTA decisions and public funding of pharmaceuticals in a selection of European countries, namely UK, 
France, and the Netherlands: 
 National Institute for Health and Care Excellence (NICE), England and Wales);  
 Scottish Medicines Consortium (SMC), Scotland  
 College voor Zorgverzekeringen (CVZ), the Netherlands   
 Haute Autorité de Santé (HAS – French Health Authority), France  
Descriptions of these four HTA bodies are provided as supplementary material (part 1).   
Specifically, the analysis aimed to (i) assess whether these HTA bodies differ amongst themselves in terms of 
the coverage decisions they make, while adjusting for a range of confounding factors; and (ii) explore the 
factors that contribute to explaining the variability in coverage decisions made by the four HTA bodies in 2004-
2009.  
2. Methods 
2.1 Explanatory Variables 
It was hypothesised, based on the nature of the HTA bodies selected and the literature available, that 
decisions are driven by the HTA decision-making process itself, the evidence considered within that process, 
and by the socio-economic and political context in which decisions are made (further information provided as 
supplementary material, part 2).  Research has shown that the evidence related to the medicine under review 
(whether clinical, economic or otherwise) can have an impact on HTA decisions (2-8).  The literature examining 
the HTA appraisal process provides insights into a number of process-related factors that can potentially 
influence decisions (9-12).  Indeed, reference in the literature is made to the impact of broader healthcare and 
welfare characteristics on HTA decision-making, such as healthcare spending per capita, societal willingness to 
pay, the structure of the healthcare system, as well as ethical and social considerations (13-17).  In line with 
the hypothesised drivers of HTA decision-making, 29 variables were identified, shown in Table I.   
2.2 Sample 
The choice of HTA body included in the analysis aimed to maximize the chance of obtaining useful data to 
address the research question, provide a comprehensive platform for analysis of the research question rather 
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than the examination of a particular factor in isolation, and to allow for the exploration of variation in the 
implementation and drivers of HTA decision-making.  To gather information on variables related to the 
coverage decision for specific technologies, data were required from HTA bodies that published their appraisal 
decisions and rationale for those decisions in a comprehensive format that was accessible to the public.   To 
this end, pharmaceutical technology appraisals performed by NICE, SMC, CVZ and HAS were selected to 
provide the sample for this analysis.  To capture a sufficient number of appraisals for both individual and 
aggregate analyses, a five-year time horizon was implemented.  Data extraction by one of the authors (KC) 
took place in July 2008-December 2009.  The sample included all drug technology appraisals (as opposed to 
medical devices or other interventions) made during the period January 2004-June 2009, indicated for an adult 
population (aged over 17 years).  Technology appraisals were excluded from the analysis for any of the 
following reasons:  if they focused on a non-adult population; if they appraised non-drug interventions; if 
marketing authorisation was withdrawn; if the Amélioriation du Service Médicale Rendu (ASMR) rating was 
not reported (HAS only); if an abbreviated or independent review panel (IRP) guidance was issued (SMC only); 
or if the full guidance was not available.   
The French HAS issued 2600 recommendations in 2004-2009. Given resource constraints, it was not possible to 
review all of these recommendations, thus the HAS sample was restricted to technologies appraised by 
SMC/NICE.  While it is understood that this approach may lead to selection bias, the benefit derived was that it 
increased the opportunity for comparability across agencies, by collecting information on a common list of 
compounds and streamlining data extraction to those appraisals that were relevant for the research question.   
A data extraction form was developed to extract information from public data sources to ensure transparency, 
reproducibility and consistency.  The resulting extracted data was coded and prepared for analysis.  The 
variable definitions and data sources used are shown in Table I. 
 
2.3 Outcome variable 
To determine the appropriate outcome variable, the approach to decision-making was assessed for each HTA 
body.  In the period 2004-2009, HAS used a five-point scale known as the ASMR rating, that classified a 
technology according to the level of incremental medical service rendered, with the highest level (I) indicating 
a high incremental medical service and the lowest (V) denoting no additional medical benefit. Subsequent 
pricing and volume negotiations were then based on these ratings.  Similarly, the CVZ has several possible HTA 
options in its armamentarium:  the GVS 1A or 1B reimbursement list, or specific reimbursement policies (e.g. 
the expensive drug list, or list ‘2’), according to whether the technology is for inpatient or outpatient use, or 
have special conditions associated with their use.   The SMC utilises a three-category approach:  accepted for 
use, accepted for restricted use and not accepted for use in NHS Scotland, therefore clearly not operating in a 
binary-type HTA decision system.  Similar to the SMC, NICE either recommends, recommends with conditions 
or does not recommend technologies for NHS funding in England and Wales.  In all four HTA bodies, decisions 
are based on more than a binary decision-process.  This was a key justification for developing a non-binary 
modelling approach.  In addition, previously published analyses have also utilised non-binary approaches 
(6,18).  The analysis used a standardised three category outcome variable where the new technology could be:   
• recommended for routine use 
• recommended for restricted use 
• not recommended for use 
Our analysis focuses on the HAS and its decision-making.  Technologies with an ASMR V are considered ‘not 
recommended’ because the HAS did not find any evidence to suggest that the technology would offer 
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incremental value relative to alternative treatment options.   In other words, with an ASMR V, the HAS signals 
it finds no basis upon which to recommend the technology for use.  Economic considerations are not 
considered by the HAS, differing from the CVZ, NICE and SMC.  Price, in particular, is known by NICE and SMC 
at time of appraisal, and officially, this is not the case for the HAS.   A variable was included in the analysis to 
capture where price was known up-front during the appraisal or not (Table I).    
While a non-recommendation by CVZ, NICE or SMC generally implies no market entry, a non-recommendation 
from the HAS (ASMR V) does not preclude market entry, as this is driven by the negotiation between the 
manufacturer and the CEPS.  The CEPS is a separate committee that is responsible for finalising the price and 
volume agreements for technologies.  We were not able to include CEPS decision-making in our analysis as 
these negotiations are confidential, to our knowledge, and so would not be able to analyse the criteria driving 
CEPS decision-making.  Other research conducted on the ASMR has made a similar assumption whereby 
technologies with ASMR V were considered to represent non-recommendation (18).  Further details on how 
the outcome variable was defined are provided in supplementary material (part 3).  
2.4 Statistical Analyses 
Descriptive statistics were calculated for each variable, stratified by outcome group (recommended, restricted, 
or not recommended) and we adopted a 0.10 level of significance.  For categorical variables, we used the Chi-
squared test to test for differences in proportions across the three outcomes.  For continuous indicators, we 
used the ANOVA test to test for differences between means for normally distributed indicators and the 
Kruskal-Wallis test to identify differences between ranks of means for not normally distributed indicators. It 
was recognised that collinearity could exist as these variables were included in the multivariate analysis, and 
thus a step-by-step process was followed to look for evidence of collinearity. 
Multinomial logistic regression was used in the analysis to model the probabilities associated with the three 
types of technology appraisal outcome. Two base cases were examined in multivariate analyses: base case 
model 1 included all four HTA bodies in the pooled analysis accompanied by fixed effects, and excluded 
economic variables not common across the four (in particular ICER-related variables). Base case model 2 
included HTA bodies (NICE and SMC) that consider the cost-effectiveness of technologies to avoid imputation 
of information that was not formally considered.  In the 2004-09 period, HAS did not consider economic 
variables and the CVZ was excluded due to low reporting of ICERs within the CVZ appraisals (11% of appraisals 
reported ICERs); this is perhaps in part driven by the fact that cost-effectiveness considerations were formally 
introduced in the CVZ process only in 2006 and cost-effectiveness results are only reported for those 
technologies that are associated with an incremental therapeutic benefit to patients.  
The ‘recommended’ outcome was selected as the referent category in the analysis.  The objective of the 
analysis was to identify, ceteris paribus, the effect of a range of factors potentially associated with HTA 
appraisal decisions, and to assess which combination of factors best explains the pattern of HTA decisions. 
Given the wide range of factors considered in the analysis (see Table I) a process was developed to determine 
which explanatory variables would appear in the final specification of the model: 
• First, bivariate regression models were run to ascertain the degree of correlation between individual 
explanatory variables and appraisal decisions.  
• On the basis of these models, a subset of indicators was selected which included those variables that 
showed at least moderate significance levels (indicators with p<0.25). A preliminary model was 
estimated including these indicators. 
• The model was reduced by removing those variables with significance levels above the 0.10 threshold.  
To guarantee its stability, this ‘base’ model was re-estimated by sequentially removing one variable at 
a time and verifying the stability of the effects on the coefficient and significance level of the 
remaining estimates.  
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• The model was subsequently tested through alternative model specifications to examine its 
robustness and to assess the sensitivity of the results to different assumptions  
• As a final step, the base-case model results were presented to HTA representatives in 1-hour 
telephone interviews, to seek feedback on the variables identified within the base-case model, the 
coefficient and level of significance to assess the validity of the model.   
The application of the model-specification process outlined above facilitated the interpretation of the results 
of the models whilst allowing the analysis to explore the impact of the wide range of indicators collected in the 
study. A step-by-step process was followed to look for evidence of collinearity within the set of regressors. 
While significant effort was made to identify information relevant to the variables of interest, a small 
proportion of the data could not be found. To maximize the sample size, imputation techniques were used to 
estimate entries for the missing observations.  Missing values were replaced with regression imputation 
estimates using the ‘impute’ command in STATA software.  The imputed values obtained were then checked 
manually to ensure their face validity. In addition, dummy variables were created to identify observations with 
missing data to test in the regression models whether the lack of data was significantly associated with 
differences in the outcome variable. 
 Sensitivity analyses were performed on the base-case regression model to test for changes in the effects to 
alternative specifications of the indicators and help evaluate the robustness of the results.  The sensitivity 
analyses included: i) examining the impact of a binary (coded as: covered/not covered) rather than a three-
category outcome variable; ii) examining the impact of including only the sub-set of technologies which were 
appraised by all four HTA bodies; (iii) examining the impact of restricting the analysis to technologies indicated 
for the treatment of cancer.    
Statistical analyses were conducted using Intercooled (IC) STATA (Version 10.1 2009). 
3. Results 
Univariate Analyses 
In total, 1258 appraisals were reviewed and 977 HTA decisions made in 2004-2009 met the inclusion criteria:  
118 NICE decisions, 288 SMC decisions, 256 CVZ decisions and 315 HAS decisions (Figure I).  281 appraisals 
were excluded from the analysis, most commonly because they were abbreviated submissions, or because 
they focused on non-adult populations (Figure I).  Within this data set, 27% of the decisions recommended 
funding of the technology, 39% restricted funding and 35% did not recommend funding the technology.  HTA 
bodies differed in the pattern of decision-making (p<0.001, Figure II a).  The most common decision by NICE 
was to restrict funding (58%), whereas for the CVZ the most common decision was to recommend (51%)
1
.  For 
both the SMC and HAS, the most common decision was to not recommend (46% and 44%, respectively).  
When a sub-sample of those technologies common across all four HTA bodies was examined (n=192, listed in 
supplementary material, part 4), differences in the pattern of decision-making between them was maintained 
(p<0.05, Figure IIb).   The trends in HTA decisions over time (January 2004 - June 2009) for each HTA body are 
presented in Figure III.  These data suggest that within HAS and NICE there has been a decrease in the 
proportion of positive recommendations made over time and a corresponding increase in the proportion of 
                                                          
1
 While prices of 1A listed technologies are pre-defined based on already existing reference technologies,  it is 
the manufacturer that submits a proposal with a price in the anticipated range according to the therapeutic 
differentiation of the product, and it is not the CVZ who asks for a price reduction to meet the reference price 
rule as a result of the appraisal.  In addition, both 1A and 1B result in similar coverage from the patient 
perspective.  This is why we decided to consider both 1A and 1B listings recommendations by the CVZ. 
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non-recommendations.  The CVZ and SMC, on the other hand, appear to have maintained a relatively stable 
pattern of decision-making over time. 
Univariate analyses showed that within the multi-HTA sample, a range of factors may play an important role in 
determining HTA decision-making.  For these variables (Table II), statistically significant differences were 
observed between interventions that were recommended, restricted and not recommended (p ≤ 0.10).  
Univariate analyses stratified by HTA agency can be found in supplementary material (part 5).    
Multivariate Analyses 
Base Case Model 1 
Base case model 1 included 20 variables yielding a pseudo R-squared of 0.13, suggesting that the model 
explains approximately 13% of the variability in HTA decisions across the multi-HTA sample (Table III).  
 One of the objectives of this analysis was to assess whether differences between HTA bodies in the pattern of 
decision-making after adjusting for a broad range of covariates. When the impact of NICE, SMC and HAS on 
HTA decisions was examined relative to the CVZ, the results suggest that NICE and HAS assessment bodies are 
strongly associated with a decreased odds of a restriction or non-recommendation.  This can be contrasted 
with the effect of the SMC, which was found to statistically significantly increase the log-odds of both 
restriction and non-recommendation in all base case models.  The impact of the HTA body was highly 
statistically significant across all assessments, while adjusting for a range of confounders.    
With regard to clinical variables, a higher number of RCTs, and the inclusion of an active comparator in the trial 
design had a significant impact on the log-odds of recommendation versus restriction or non-
recommendation.  Specifically, if the technology was compared to an active control rather than placebo, the 
log-odds for restriction relative to recommendation decreased (p=0.011), as did the log-odds of non-
recommendation relative to recommendation (p=0.001), while holding all other variables constant.  If the 
technology demonstrated clinical superiority, the log-odds for restriction relative to recommendation 
decreased (p=0.023), as did the log-odds of non-recommendation relative to recommendation (p=0.001), 
while holding all other variables constant. Orphan designated pharmaceuticals were less likely to be rejected 
(p=0.023).   
Process factors had a significant impact on HTA decisions in this multi-HTA analysis.  An increase in the number 
of technologies appraised simultaneously exerted a bigger impact on the log-odds of a restriction (p=0.002). 
The inclusion of patient submissions and patient evidence as part of the process was linked with an increase in 
the log-odds of a restriction (p=0.008).   
Socio-economic factors contributed to explaining the variability in HTA decisions across the HTA bodies.  With 
regard to the size of the population within the HTA body remit, a unit increase in the population size increased 
the odds of both restriction and non-recommendation, and both effects were statistically significant.      
Base Case Model 2 
Base case model 2 (NICE and SMC) included 19 variables yielding a pseudo R-squared of 0.16, suggesting that 
the model explains approximately 16% of the variability in HTA decisions across the multi-HTA sample (Table 
IV).    
With regard to clinical variables, as in base case model 1, a higher number of RCTs, and the inclusion of an 
active comparator in the trial design had a significant impact on the log-odds of recommendation versus 
restriction or non-recommendation.  Specifically, if the technology was compared to an active control rather 
than placebo, the log-odds for restriction relative to recommendation decreased (p=0.05), as did the log-odds 
of non-recommendation relative to recommendation (p=0.022), while holding all other variables constant.  No 
impact of orphan status was identified in base-case model 2.  
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With regard to economic variables, a unit increase in the ICER was shown to increase the odds of restriction 
(p=0.011) and the log odds of non-recommendation (p=0.001), relative to recommendation. 
Process factors had a significant impact on HTA decisions in this multi-HTA analysis.  Relative to 
recommendation, an increase in the number of technologies significantly increased the odds of both 
restriction (p=0.001) and non-recommendation (p=0.074).  No effect on decision was found for either patient 
submissions or patient evidence.  
Socio-economic factors contributed to explaining the variability in decisions across the HTA bodies.  A unit 
increase in the population size within the HTA body remit increased the odds of both restriction and non-
recommendation, and both effects were statistically significant.      
Sensitivity Analyses 
The results of a series of sensitivity analyses suggest that the base case models are robust.  A sensitivity 
analysis was conducted using a binary outcome variable, providing similar results to the base-case multi-HTA 
analysis.  Sensitivity analyses were also conducted on the sample of technologies indicated for cancer 
treatment (247 appraisals of 977) as well as on a sub-set of the sample  including only those technologies 
appraised by all four HTA bodies at least once (192 appraisals of 977). The results of these analyses suggest 
that, compared to the base case model 1, the explanatory power of the combination of clinical, process and 
socio-economic factors is twice as high when including only those technologies from the same disease area or 
technologies that all four HTA bodies hold in common (as implied by the higher pseudo R-squared: 0.26 and 
0.27 in these sub-analyses respectively, compared with 0.13 in the base-case multi-HTA analysis).   
For each HTA agency, a summary of the statistically significant explanatory variables identified in descriptive 
and multivariate analyses is given in Table V.  
4. Discussion 
This study aimed to untangle the factors driving funding decisions by conducting multivariate analyses of 977 
decisions observed within a multi-HTA data set of appraisals performed by four European HTA agencies: NICE, 
SMC, CVZ and HAS.  Previous comparative analyses across HTA bodies identified in the literature were 
primarily qualitative or adopted descriptive quantitative methodologies ( 5,18-20).  Such descriptive analytical 
techniques make it difficult to interpret the relative contribution of each factor, given the absence of 
adjustment for other factors in the analysis.  In contrast, we created a bespoke dataset of HTA coverage 
decisions from four European HTA bodies over a five-year period and utilised statistical analysis to assess the 
relative contribution of a comprehensive range of factors on coverage decisions. 
Significant variability in decision-making across HTA bodies 
Addressing the first objective, the analysis confirmed that observed differences in decision-making by HTA 
agencies remained after adjusting for a range of factors including scoping, evidence considered, process and 
socio-economic differences.  On average, 27% of the decisions (ranging from 18% in HAS to 51% in CVZ) 
recommended funding of the technology, 39% restricted funding (range 33% CVZ to 58% NICE) and 35% did 
not recommend funding the technology (range 14% NICE to 46% SMC) (Figure IIa).  Indeed, HTA bodies differ 
significantly even when the analysis is restricted to coverage decisions made for the same set of technologies 
(Figure IIb).  From one perspective, such differences in coverage patterns and the factors that drive decisions 
can be explained by the fact that each HTA body is designed to match as closely as possible the specific 
healthcare system it serves.  Therefore, variation observed across HTA bodies could be considered to reflect 
the reality of healthcare market variations between countries.  However, from another perspective, 
differences in the proportion of recommendations, restrictions and non-recommendations might be seen to 
be contrary to the principle of equitable access to treatment in Europe.   
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In particular, non-recommendation was observed in 14% and 16% of NICE and CVZ coverage decisions, and 
44% and 46% of HAS and SMC coverage decisions, respectively.  These technologies were not recommended 
for reimbursement despite obtaining a license for use within Europe from regulatory agencies, primarily the 
European Medicines Agency (EMA).  Differences in the criteria used to assess the value of new technologies 
between the EMA and HTA bodies could be seen as a key driver of this situation.  This suggests there could be 
potential for efficiencies in the regulatory and HTA processes so that effort is not spent on generating 
marketing authorizations for a significant proportion of technologies that end up not being recommended for 
reimbursed use by HTA bodies.      
Explaining the variability in decision-making – so much for ‘untangling’? 
The second objective of this analysis was to explore the factors that contribute to explaining the variability in 
coverage decisions made by the four HTA bodies in 2004-2009.  The degree of ‘untangling’ achieved was 
limited given that multivariate analyses could only explain between 13% and 30% of the observed variability in 
decision-making, despite taking into account a wide range of variables.   A higher proportion of the variability 
could be explained when limiting the analysis to a common set of technologies evaluated by all HTA bodies.  
This suggests that the variability in HTA outcomes may in part be driven by the heterogeneity observed in the 
technologies selected for appraisal.  However, even when this heterogeneity is managed by focusing the 
multivariate analysis on a subset of technologies that are either commonly appraised across HTAs or focus on a 
single disease area, more than 70% of the variability in decision-making could not be explained. 
Indeed, whether the technology was appraised by one HTA or another was found to have a statistically 
significant effect on the outcome, even when adjusting for a range of confounding factors.    Relative to the 
CVZ, the results suggest that NICE and HAS are associated with a higher probability of recommendation, while 
the SMC is associated with a higher probability of both restriction and non-recommendation.  This may be due 
to the fact that the HTA body is surrogate for other variables and thus that additional variables needed to be 
included, alternative methods of analysis tested, and/or that decision-making is partly random. This result 
echoes in part results from Clement et al. (5) reporting statistically significant differences in the nature of the 
HTA decisions made by NICE, PBAC and CDR.  Our analysis would support the view that while evidence-based 
assessment of technologies is a key part of the HTA process, decision-making is ultimately driven by a range of 
factors that appear to be highly specific to each HTA body. 
The strength of the evidence demonstrating the clinical value of the pharmaceutical, together with the 
therapeutic area which it targets, have a significant role in HTA decisions.  Interestingly, there were some 
specific variables which appeared to have an impact (such as demonstration of clinical superiority), while other 
clinical/disease evidence variables did not show any effect in the multivariate analyses (e.g. number of 
observational studies).  This raises the question as to whether it would be of benefit for HTA bodies and 
manufacturer submissions (and clinical trials) to streamline the submission and review of clinical evidence that 
most drives decision-making, encouraging more efficient HTA assessments.  There were no other published 
cross-HTA multivariate studies available for comparison, although single-HTA analyses have identified a range 
of clinical evidence characteristics associated with HTA outcomes (21).   
The multi-HTA analysis of NICE and SMC appraisals (more than 400 of which were analysed here), representing 
one of the largest analyses of the effect of cost-effectiveness on HTA decision-making, confirmed the 
hypothesis that the effect of the ICER is similar to that observed in individual HTA analyses ( 6,7,22): a higher 
ICER decreases the probability of recommendation, an effect that is highly statistically significant in our 
analyses.  While CVZ and HAS were excluded from this analysis due to limited consideration (CVZ)
2
 or no 
                                                          
2
 It should be noted that since 2005, CVZ has increasingly used cost-effectiveness evidence in its decision-
making, in particularly for technologies evaluated for 1B listing and specific instances.  However, because of 
the fact that in the sample of CVZ decisions between 2004-2009 only 11% of technologies (<30) were 
supported by reported ICER data, it was not included in base case model 2 
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consideration (HAS) of cost-effectiveness evidence, since the time of this analysis both HTA bodies have 
increased the role of economic criteria in their decision-making.   
This multi-HTA analysis finds support for the role of process factors in explaining decision-making, in particular 
the role of patient evidence, and the impact of single versus multi-technology appraisals.  The multivariate 
analyses confirmed that an increase in the number of technologies appraised simultaneously increased the 
probability of restriction and non-recommendation.  This would suggest that in circumstances where multiple 
technologies are being appraised simultaneously, a ‘winner’ is more likely to be selected, with the remainder 
being restricted or not recommended for funding. This has implications when considering the efficiencies that 
may be gained in the appraisal process by coupling the review of multiple technologies together, against the 
time-lag that this may create in access to new medicines, depending on how frequently multi-technology 
reviews are conducted.        
National population size had a significant impact on HTA decision-making in this multi-HTA analysis, an effect 
not previously observed in individual HTA analyses ( 5-6,22).  Greater population size decreased the probability 
of recommendation.  It is not clear to what extent this reflects the effect of the absolute size of the patient 
population eligible for treatment: this variable also increases the odds of restriction and non-recommendation, 
but its effect is only significant in base case model 1 (on odds of restriction relative to recommendation).  It is 
plausible that population size may serve as a proxy for the budget impact of adopting a technology, but when 
the budget impact variable was introduced in additional sensitivity analyses, it was not significant.        
Limitations 
We focused specifically on pharmaceutical technologies as we wanted to generate a sample of technologies 
representative of the majority of decisions made by the HTA bodies included in the study.  Thus results of this 
analysis are not readily generalizable to non-pharmaceutical technologies.  The selection of HTA bodies for 
inclusion in this analysis was driven by the objectives of the study, and in addition HTA bodies were selected 
that reported their appraisals in English, French or Dutch (to make it feasible for us to collect our primary 
data).   
The potential for information bias, particularly in how the outcome and explanatory variables were defined 
and extracted for each HTA body, was recognised, and a data extraction protocol and process was defined to 
limit inconsistencies in the extraction process.  However, there are still limitations.  In particular, decisions are 
communicated differently across HTA bodies:  HAS uses ASMR ratings to define incremental therapeutic value, 
CVZ attributes technologies to different reimbursement lists, SMC uses a three-category system and NICE a 
binary category system.  In addition, the use of the ‘restricted’ category in this analysis is challenged by the 
fact that inter- and intra-HTA differences exist in how it is applied.   
The generalizability of the results is further constrained by the fact that HTA appraisal processes are subject to 
change (for example, the potential introduction of value-based pricing in UK in 2014, changes in France with 
increasing consideration for medico-economic evidence in 2013), and thus the results obtained are specific to 
2004-2009. HTA bodies, both within and outside Europe, vary in their objectives, and in the approach and 
methods used to implement HTA within their jurisdictions.   
Socio-economic indicators such as GDP are known to be influenced by many different factors.  Indeed, such 
indicators act as a surrogate for many characteristics of the countries to which they apply.  In addition, such 
indicators that vary at the HTA body level, rather than the technology appraisal level, are unlikely to have a 
very strong effect, due to the limited number of HTA bodies in this analysis.  Therefore, the interpretation of 
the impact of such broad indicators, such as the percentage of GDP spent on healthcare, will need to take into 
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consideration the risk that variations observed in such indicators across HTA bodies may be correlated with 
other factors.   
Given the heterogeneity in decision-making observed in this analysis, extrapolating to other HTA bodies not 
included in this research is not advisable without having a more concrete understanding of their decision-
making processes and the outcome definition used.    
Implications 
This analysis involved an intensive data collection exercise lasting 18 months: information about HTA decision-
making and the characteristics of a technology, the appraisal process and the context in which decisions are 
made, is not readily available.  It raises interesting questions about the role of transparency in decision-
making, in particular to what extent any transparency which exists at the level of individual technology 
appraisals should be extended to transparency in the outcome and drivers of decision-making for the decisions 
made by HTA bodies.   
The implications of this analysis in the light of the increasing collaboration between European HTA bodies 
through EUnetHTA should be addressed.  A key project ongoing within EUnetHTA is the HTA Core Model for 
Rapid Relative Effectiveness Assessment of Pharmaceuticals: the “HTA Core Model defines the content 
elements to be considered in an HTA and facilitates standardised reporting. The aim is to share information, to 
avoid duplication of work, and to facilitate the adaptation of information in national HTA reports and the co-
production of HTA reports (by multiple HTA agencies)” (EUnetHTA accessed 2013).  This core-model concept 
assumes that there is overlap in the timing of when pharmaceutical appraisals take place, and overlap in the 
scoping practices of HTA bodies. In the sample covered in this study, only 10% of technologies were appraised 
by all four HTA bodies, and significant differences in the timing of appraisals were observed.  This has 
implications in terms of the co-ordination and timing of centralised HTA Core Model initiatives to ensure that 
they have maximum relevance to the HTA stakeholders they wish to serve.  This analysis may also help to 
inform which types of evidence might best be included in the Core Model, based on those variables which 
appear to have the most effect in explaining payer decisions.   
The framework adopted in our analysis, notwithstanding its limitations, provides an example of a 
comprehensive analytical approach for understanding coverage decision-making. While recognising the 
diversity in scope, objective and context in which different HTA bodies operate, convergence towards an 
analytical framework for the analysis of coverage decisions in future research may be of value.  
5. Conclusions 
In this European multi-HTA study, a comprehensive and multivariate analytical approach found that clinical, 
process, socio-economic factors and an “HTA-agency effect” explained part of the observed variability in HTA 
decisions, helping to untangle some aspects of decision-making.  However, this extensive analysis of HTA 
decision-making could explain no more than 30% of the observed variability, suggesting that while some 
aspects of decision-making have been ‘untangled’, greater transparency of decision-making is needed, along 
with associated further research.    
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Figures and tables 
 
Figure I.  Flowchart of Multi-HTA dataset including technology appraisals performed by NICE, SMC, CVZ and HAS 
during 2004-2009 
 
 
 
Legend: 
TA- Technology Appraisals; NICE –National Institute for Health and Care Excellence (NICE); Scottish Medicines 
Consortium (SMC); College voor Zorgverzekeringen (CVZ); Haute Autorité de Santé (HAS) 
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Figure II a. Distribution of type of HTA coverage decisions on pharmaceutical technologies by NICE, SMC, CVZ 
and HAS in 2004-2009 (n=977) 
 
Figure II b. Distribution of type of HTA coverage decisions made in 2004-2009 on subset of pharmaceutical 
technologies appraised by  NICE, SMC, CVZ and HAS (n=192) 
 
Legend: 
NICE –National Institute for Health and Care Excellence (NICE); Scottish Medicines Consortium (SMC); College voor 
Zorgverzekeringen (CVZ); Haute Autorité de Santé (HAS).  Recommended = pharmaceutical technology 
recommended for routine use; Restricted = pharmaceutical technology recommended for restricted use; Not 
Recommended = pharmaceutical technology not recommended for use 
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Figure III NICE, SMC, CVZ and HAS HTA decisions between 2004-2009 (June), by year (n=977) 
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Table I  Summary of Included Explanatory Variables, their Definition, and Data Sources 
# Variable  Unit of 
Measure 
Definition Data Sources 
Evidence – clinical and disease-related variables 
1 Number of RCTs 
considered in 
decision 
Count The number of distinct randomised controlled trials 
(RCTs) that provide data related to the therapeutic 
indication under evaluation.  Excluded: studies that are 
single-arm, have no randomization, or are non-
interventional.  
NICE: Technical Appraisal Report (TAR) Section 2 
SMC:  SMC Advice, “Summary of evidence on comparative 
efficacy” section SMC Advice 
CVZ: CFH-rapport , section 2a;  Farmacotherapeutisch 
rapport, section 3, 4a-f 
HAS:  Advice from the Commission de la Transparence, 
section 3 (3.1 – 3.3) 
 
2 Size of population 
included in RCTs 
Numeric Mean number of patients per RCT. 
3 Length/extent of 
follow-up in RCT 
Numeric Mean number of weeks over which data are collected on 
patients that entered the RCTs (see variable no. 1).  
4 Statistically 
Significant superior 
results 
Categorical 
(superior/
not 
superior 
/inconsiste
nt results) 
Presence of statistically significant superiority of 
technology vs. comparator for primary endpoint(s). If 
the technology showed statistically significant 
superiority in one trial, but not in another, the results 
were considered to be ‘inconsistent’.  RCTs designed as 
‘non-inferiority’ studies were classified as not 
demonstrating superiority (i.e. ‘no’).  
NICE: Technical Appraisal Report (TAR) Section 4 
SMC: SMC Advice, “Summary of evidence on comparative 
efficacy” section SMC Advice 
CVZ: CFH-rapport , section 2a;  Farmacotherapeutisch 
rapport, section 3, 4a-f 
HAS: Advice from the Commission de la Transparence, 
section 3 (3.1 – 3.3) 
5 Use of active 
comparator 
Numeric Percentage of RCTs where active comparator was used, 
as opposed to placebo.  
NICE: Technical Appraisal Report (TAR) Section 4 
SMC: SMC Advice, “Summary of evidence on comparative 
efficacy” section SMC Advice;   “Summary of clinical 
effectiveness issues” section of SMC Advice; 
CVZ: CFH-rapport , section 2a;  Farmacotherapeutisch 
rapport, section 3, 4a-f 
HAS: Advice from the Commission de la Transparence, 
section 3 (3.1 – 3.3) 
6 Number of 
observational 
studies considered 
in guidance 
Count Number of observational studies providing information 
to support study drug.  Observational studies are 
defined as non-interventional (i.e. do not explicitly 
request the patient to take particular medication or the 
physician to follow particular protocol).   
7 Priority disease 
area 
Categorical 
– yes/no 
This variable captures whether the pharmaceutical in 
question is linked to a disease area that is prioritized by 
the Ministry of Health. Priority disease areas were 
identified by examining government plans/health 
documents that highlight national health care system 
focus.  
NICE:  Department of Health (DH) (2002),   DH (2006a), DH 
(2006b); DH (2007) 
SMC: NHS Health Scotland (2004, 2005, 2006, 2007, 2008) 
CVZ: Ministerie van Volksgezondheid, Welzijn en Sport   
HAS:  CNRS (2004) 
8 Orphan Designated Categorical This variable captured information on whether or not European Medicines Agency [accessed 2011] 
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– yes/no the technology was recognized by the European 
Medicines Agency (EMA) as an orphan designated 
medicine.   
 
9 Therapeutic 
Indication 
Categorical 
-  12 
categories 
The British National Formulary (BNF) categories were 
used to classify each technology into the corresponding 
therapeutic area. 
British National Formulary (2010) 
10 Size of eligible 
population for 
treatment 
Numeric Reported number of patients eligible for treatment, as 
per the Summary Product Characteristics and indication 
of the medication under evaluation is indicated.  
NICE:  TAR section 2 and/or 5 
SMC: SMC Advice,  “ Additional information: budget 
impact” section; 
CVZ: CFH-rapport , section 2a  Farmacotherapeutisch 
rapport, section 3, 4a-f 
HAS: Advice from the Commission de la Transparence, 
section 4.4 
11 Availability of 
alternative 
therapies in current 
treatment setting. 
Categorical 
– yes/no  
An alternative was considered to be available if 
comparators were clearly defined in the review by the 
HTA agency.  An alternative was considered NOT 
available if it was stated as such in the appraisal, or if 
‘best supportive care’ or ‘palliative care’ was specified as 
the comparator.  
NICE: TAR section 2 
SMC: SMC Advice “ Additional information: comparators” 
section 
CVZ: CFH-rapport , section 2a;  Farmacotherapeutisch 
rapport, section 3, 4a-f 
HAS: Advice from the Commission de la Transparence, 
sections 2.2 and 2.3, and 4.3 
Evidence – economic variables 
12 Consideration of 
Cost Utility Analysis 
in guidance 
Categoric
al – CUA 
performe
d or no 
CUA 
Presence or absence of a cost-utility analysis.    NICE: TAR section 4/ 5 
SMC: SMC Advice “ Summary of comparative health 
economic evidence” section 
CVZ: Farmaco-economisch rapport and Vraagstelling 
doelmatigheidstoets; 
HAS: Secretariat General de la Commission de la 
Transparence (2005) 
13 Incremental Cost-
utility ratio of 
technology vs. 
comparator in base 
case 
Numeric ICER (cost per QALY) included in the report for base case 
as accepted by the HTA body.  This is defined as the ICER 
that is related to the recommendation.  If more than one 
ICER is presented (as the recommendation covers more 
than one population) then the ICER pertaining to the 
larger of the populations was reported. If technology is 
reported as dominant or dominated, it was recorded as 
such on the data extraction sheet.   
This variable was not applicable to the HAS.   
NICE: TAR section 4/ 5 
SMC: SMC Advice “ Summary of comparative health 
economic evidence” section 
CVZ: Farmaco-economisch rapport and Vraagstelling 
doelmatigheidstoets; 
HAS: N/A 
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14
-
15 
Multiple CUA/CEA 
models reported 
Categoric
al - 
Yes/No; If 
yes – 
provide 
range 
Variable 14 reports whether more than one cost-utility or 
cost-effectiveness model was considered during the 
appraisal (yes / no). If yes, variable 15 measures the range 
of base-case ICERs presented between the different 
models reported. The difference between the lowest and 
highest ICER was calculated.  
This variable was not applicable to the HAS.   
16 Uncertainty around 
the base case ICER 
reported in 
submission 
(probabilistic) 
Numeric  Measures the percentage probability of acceptance at the 
threshold used by the agency.  For the CVZ the probability 
of the medication being cost-effective was reported at a 
EUR €50,000 threshold; for NICE and SMC, a threshold of 
20,000GBP was used.   This variable was not applicable to 
the HAS.   
17 Uncertainty around 
base case ICER 
reported in 
submission 
(univariate) 
Numeric Measured the range of ICERs (min-max) resulting from 
univariate sensitivity on the base case.     
This variable was not applicable to the HAS.   
NICE: TAR section 4/ 5 
SMC: SMC Advice “ Summary of comparative health 
economic evidence” section 
CVZ: Farmaco-economisch rapport and Vraagstelling 
doelmatigheidstoets; 
HAS: N/A 
18 Anticipated 
budgetary impact 
of introduction of 
new technology in 
health care system 
Numeric Estimated annual budgetary impact of introducing new 
medication into the current treatment setting, if the 
pharmaceutical were to be introduced without any 
restriction.  Drug cost only (per year).   
This variable was not applicable to the HAS.   
NICE: TAR section 4/ 5 
SMC: SMC Advice,  “ Additional information: budget 
impact” section 
CVZ: Kostenprognose Rapport 
HAS: N/A 
Decision-making process variables 
19 Inclusion of patient 
submission 
Categori
cal – 
yes/no 
A patient submission was considered to have been 
included as part of the appraisal process if a submission 
from a patient group was posted on the webpage 
pertaining to the guidance.  
NICE: NICE (2011) section describing the history of the 
appraisal 
SMC:  SMC Advice, “ Summary of patient and public 
involvement” section 
CVZ: College voor zorgverzekeringen: Cvz-criteria voor 
beoordeling therapeutische waarde, 2010 
HAS: Secretariat General de la Commission de la 
Transparence (2005) 
20 No. of decision 
makers 
accountable 
Numeric Captures the number of committee members accountable 
for the guidance issued, as reported in the HTA process 
guidelines.  
NICE: TAR Appendix B of each guidance 
SMC: SMC Meeting Minutes,  
http://www.scottishmedicines.org.uk/About_SMC/Minute
s/Minutes 
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CVZ: College voor zorgverzekeringen: Cvz-criteria voor 
beoordeling therapeutische waarde, 2010 
HAS: Secretariat General de la Commission de la 
Transparence (2005) 
21 Cost-effectiveness 
evaluation 
component in 
process 
Categori
cal – 
yes/no 
Captures whether or not cost-effectiveness is a component 
of the decision-making process. If cost-effectiveness 
analysis is a formal part of the appraisal process, this 
variable was marked as ‘yes’.  
NICE: TAR / NICE (2008b) 
SMC: SMC Advice,  SMC (2010b) 
CVZ: College voor zorgverzekeringen: Cvz-criteria voor 
beoordeling therapeutische waarde, 2010 
HAS: Secretariat General de la Commission de la 
Transparence (2005) ; Sorenson et al. (2008) 
22 Budget impact 
evaluation 
component in 
process 
Categori
cal – 
yes/no 
Captures whether budget impact considerations are part of 
decision-making process 
23 Price Known during 
appraisal 
Categori
cal – 
yes/no 
Captures whether the price of the technology under 
appraisal was known during the assessment 
NICE: TAR section 3 
SMC: SMC Advice,  SMC (2010b) 
CVZ: College voor zorgverzekeringen: Cvz-criteria voor 
beoordeling therapeutische waarde, 2010 
HAS: Secretariat General de la Commission de la 
Transparence (2005)  
24 Number of drugs 
appraised in same 
appraisal 
Count This variable captures the number of technologies 
appraised simultaneously in the appraisal 
NICE: TAR cover page 
SMC:  SMC Advice,  SMC (2010b) 
CVZ: College voor zorgverzekeringen: Cvz-criteria voor 
beoordeling therapeutische waarde, 2010;  CFH-rapport , 
section 2a;   
HAS: Secretariat General de la Commission de la 
Transparence (2005)  
Socio-economic and system context variables 
25 Date guidance was 
issued 
Numeric Year when coverage decision was issued (11) NICE: TAR cover page 
SMC: Decision cover page 
CVZ: Letter from the minister van Volksgezondheid, 
Welzijn en Sport 
HAS: Cover Page of Avis from the Commission de la 
Transparence 
26 Healthcare exp as 
% GDP 
Numeric 
(%) 
Percentage of GDP spent on healthcare, during year of 
decision  
 OECD Health Data 2009, OECD 2010 
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27 Healthcare 
expenditure on 
pharmaceuticals  
Numeric 
(€) 
Healthcare budget spent on pharmaceuticals per patient 
per year, during the same year in which the appraisal was 
published. (12, 13)  
NICE: Association of the British Pharmaceutical Industry 
(2010) 
SMC: ISD (2009) 
CVZ:  Centraal Bureau voor de Statistiek (CBS)Statline ;  
GIPdatabank ,  
HAS: Econ-Sante` France (2010) ;  IRDES (2009)  
28 National Population 
Size 
Numeric Estimate of population size within remit of the agency 
performing the evaluation. 
NICE: National Office of Statistics (2009) 
SMC: National Office of Statistics (2009) 
CVZ:  Centraal Bureau voor de Statistiek (CBS)Statline 
HAS: Eurostat (2010) 
29 Election year at 
time of decision 
Categoric
al – 
yes/no 
This variable captures whether the payer decision was 
made within an election year.  An election year was 
defined as a year in which either national government or 
regional elections took place.  (13)    
NICE: BBC 2005 
SMC: BBC 2005, BBC 2007 
CVZ: Todosijevic et al 
HAS: Le ministre de l'intérieur, de l'outre-mer, des 
collectivités territoriales et de l'immigration (2004) and 
(2007)   
Legend:  RCT=Randomised Controlled Trial;  HTA= Health Technology Assessment;  CUA= Cost Utility Analysis; CEA=Cost Effectiveness Analysis;  NICE –National Institute for 
Health and Care Excellence (NICE); Scottish Medicines Consortium (SMC); College voor Zorgverzekeringen (CVZ); Haute Autorité de Santé (HAS).   
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Table II Descriptive Statistics of pooled sample of coverage decisions from NICE, SMC, CVZ and HAS (n= 977) by HTA coverage decision (recommended, restricted or not 
recommended) (n=977) 
 Recommended Restricted Not Recommended P value 
Variable Mean 95% CI   Mean 95% CI   Mean 95% CI     
Clinical, Disease Variables           
Number of RCTs considered in decision 2.7 2.1 3.3 3.4 2.9 3.8 2.6 2.3 2.9 <0.05 
Size of population included in RCTs 967 687 1247 1251 914 1587 830 607 1053 NS 
Length/extent of follow-up in RCT 
(weeks) 
58.4 50.4 66.3 49.1 42.9 55.4 41.4 34.6 48.2 <0.01 
Statistically Significant superior results 
                    Superior 49% 43% 55% 42% 37% 47% 39% 33% 44% <0.05 
                    Not superior 15% 11% 20% 16% 13% 20% 18% 14% 23% <0.01 
                    Inconsistent results 20% 15% 25% 32% 27% 37% 29% 24% 34% NS 
Use of active comparator 52% 46% 58% 45% 40% 49% 43% 38% 48% NS 
Number of observational studies 
considered in guidance 
0.6 0.3 0.8 0.3 0.2 0.4 1.2 -0.3 2.7 <0.05 
Priority disease area 64% 58% 70% 62% 57% 67% 63% 58% 68% NS 
Orphan Designated 11% 7% 15% 9% 6% 12% 8% 5% 11% NS 
Therapeutic Indication           
cardiovascular system 10% 6% 13% 12% 9% 15% 11% 7% 14% NS 
central nervous system 12% 8% 15% 19% 15% 23% 23% 19% 28% <0.01 
ear, nose and oropharynx 1% 0% 3% 0% 0% 0% 0% 0% 1% <0.05 
endocrine system 4% 2% 7% 7% 5% 10% 6% 4% 9% NS 
Eye 3% 1% 5% 1% 0% 2% 1% 0% 2% <0.05 
gastro-intestinal system 3% 1% 6% 2% 1% 4% 6% 3% 9% <0.05 
Infections 9% 6% 12% 12% 9% 16% 10% 7% 13% NS 
malignant disease and 
immunosuppression 
34% 29% 40% 22% 18% 26% 21% 17% 26% <0.01 
musculoskeletal and joint 
diseases 
10% 7% 14% 12% 9% 15% 5% 2% 7% <0.01 
nutrition and blood 6% 3% 9% 4% 2% 6% 5% 3% 8% NS 
obstetrics, gynaecology, and 
urinary-tract disorders 
0% 0% 1% 2% 1% 4% 1% 0% 2% <0.05 
respiratory system 1% 0% 2% 1% 0% 2% 6% 3% 9% <0.01 
Skin 4% 2% 7% 5% 3% 7% 4% 2% 6% NS 
Size of eligible patient population 105,118  44,430  165,805   746,591  363,878  1,129,304  561,944  326,147  797,741  <0.05 
Availability of alternative therapies in 82% 77% 86% 86% 83% 90% 85% 81% 89% NS 
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 Recommended Restricted Not Recommended P value 
Variable Mean 95% CI   Mean 95% CI   Mean 95% CI     
current treatment setting 
Economic Variables           
Consideration of Cost Utility Analysis 
in guidance 
31% 26% 37% 39% 34% 44% 37% 31% 42% NS 
Incremental Cost-effectiveness ratio of 
technology vs. comparator in base 
case 
£20,151 £12,203 £28,099 £25,358 £18,523 £32,193 £50,253 £29,179 £71,326 <0.05 
Multiple CUA/CEA models reported 12% 7% 16% 17% 12% 21% 6% 3% 10% <0.01 
Lowest reported ICER £16,256 £4,175 £28,336 £13,141 £9,888 £16,393 £20,201 £10,459 £29,944 <0.01 
Highest reported ICER £95,652 £6,764 £184,540 £125,859 £82,185 £169,533 £69,600 £28,140 £111,059 <0.01 
Uncertainty around the base case ICER 
reported in submission (probabilistic)  
65% 51% 78% 46% 36% 57% 23% 11% 35% <0.05 
Uncertainty around base case ICER 
reported in submission (univariate)  
Low 
£11,278 £6,677 £15,879 £14,881 £6,640 £23,123 £59,904 £17,958 £101,849 <0.05 
Uncertainty around base case ICER 
reported in submission (univariate) 
High  
£105,042 £29,268 £180,816 £42,049 £28,653 £55,445 £242,362 £75,624 £409,101 <0.05 
Anticipated budgetary impact of 
introduction of new technology in 
health care system (million £) 
£10.9 £6 £15.3 £274.6 £25.4 £523.8 £163.4 -£40 £366.7 <0.05 
Decision-Making Process variables           
Inclusion of patient submission 17% 12% 22% 27% 22% 32% 22% 18% 27% <0.05 
Number of Decision Makers 
Accountable 
24 23 25 27 26 27 27 27 28 <0.01 
Cost-effectiveness evaluation 
component in process 
64% 58% 70% 60% 55% 65% 54% 49% 60% <0.05 
Budget impact as a component of 
decision-making process 
81% 76% 86% 68% 63% 73% 57% 52% 62% <0.01 
Pricing known during appraisal 49% 43% 55% 23% 18% 27% 12% 9% 16% <0.01 
Number of drugs appraised in same 
appraisal 
1.1 1.1 1.2 1.4 1.3 1.6 1.1 1.0 1.1 <0.05 
Socio-economic context variables           
Date guidance was issued 2006 2006 2006 2006  2,006  2007 2007 2007 2007 <0.01 
GDP-healthcare expenditure 10% 9% 10% 10% 9% 10% 10% 10% 10% <0.01 
Healthcare expenditure on £263 £252 £274 £280 £269 £291 £306 £293 £320 <0.01 
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 Recommended Restricted Not Recommended P value 
Variable Mean 95% CI   Mean 95% CI   Mean 95% CI     
pharmaceuticals 
Population size – Agency coverage 
(million) 
27.50  24.80   30.20  35.30   32.70  37.90  34.10  31.10   37.10  <0.01 
Election year at time of decision 28% 22% 33% 31% 26% 35% 30% 25% 35% NS 
 
Legend:  RCT=Randomised Controlled Trial;  HTA= Health Technology Assessment;  CUA= Cost Utility Analysis; CEA=Cost Effectiveness Analysis; NICE –National Institute for 
Health and Care Excellence (NICE); Scottish Medicines Consortium (SMC); College voor Zorgverzekeringen (CVZ); Haute Autorité de Santé (HAS).  
Recommended = pharmaceutical technology recommended for routine use; Restricted = pharmaceutical technology recommended for restricted use; Not 
Recommended = pharmaceutical technology not recommended for use 
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Table III  Base case Model 1:  includes all four HTA bodies (but no ICER, and including fixed effects for each HTA body) (n=977) 
  Restricted vs. Recommended Not Recommended vs. Recommended 
Variables Log Odds P value 95%  Conf. Interval Log Odds P value 95%  Conf. Interval 
Number of RCTs -0.018 0.402 -0.061 0.025 -0.060 0.058 -0.122 0.002 
RCT duration of follow-up -0.001 0.453 -0.0044 0.00198 -0.003 0.112 -0.007 0.001 
Use of active comparator in RCT -0.535 0.011 -0.949 -0.121 -0.932 <0.001 -1.383 -0.481 
Clinical superiority demonstrated in RCT -0.433 0.023 -0.807 -0.059 -0.762 <0.001 -1.176 -0.349 
Therapeutic Indication          
Central nervous system 0.213 0.464 -0.357 0.784 0.381 0.209 -0.213 0.976 
Eye -1.443 0.047 -2.866 -0.021 -1.314 0.075 -2.761 0.134 
Malignancy/immunosuppresion therapy -0.532 0.031 -1.016 -0.048 -0.457 0.087 -0.981 0.067 
musculoskeletal and joint diseases -0.200 0.536 -0.833 0.433 -0.958 0.017 -1.747 -0.169 
obstetrics, gynaecology, and urinary-tract disorders 2.292 0.034 0.171 4.413 1.700 0.148 -0.603 4.003 
Respiratory system 0.492 0.511 -0.974 1.958 1.747 0.012 0.378 3.116 
Cardiovascular disease 0.067 0.828 -0.540 0.675 -0.290 0.39 -0.952 0.372 
Skin -0.011 0.980 -0.856 0.834 -0.302 0.529 -1.242 0.639 
Orphan designation status -0.311 0.294 -0.891 0.269 -0.749 0.023 -1.397 -0.101 
Size of eligible patient population 5.00E-07 0.093 -0.00000134 0.00000010 0.000 0.633 0.000 0.000 
Patient submission included 0.391 0.203 -0.211 0.993 0.833 0.008 0.215 1.452 
Number of technologies appraised simultaneously 0.523 0.002 0.197 0.849 0.146 0.546 -0.328 0.620 
National population size 0.0000005 0.024 0.00000007 0.0000009 0.000 <0.001 <0.001 <0.0001 
NICE* -18.526 0.027 -34.957 -2.096 -37.714 <0.001 -55.265 -20.163 
SMC* 6.666 0.0080 1.761 11.571 13.270 <0.001 8.034 18.506 
HAS* -22.156 0.033 -42.550 -1.762 -44.951 <0.001 -66.727 -23.175 
Constant -8.412 0.022 -15.589 -1.235 -16.638 <0.001 -24.299 -8.977 
Note:  Recommended technologies are the reference case. Multinomial logistic regression, pseudo R-squared: 0.13.  * Please note, CVZ is referent.   
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Table IV. Base-case Model 2:  Multivariate analysis of multi-HTA sample of NICE and SMC HTA coverage decisions 2004-2009 (n=406) 
  Restricted vs. Recommended Not Recommended vs. Recommended 
Variables Log Odds P value 95%  Conf. Interval Log Odds P value 95%  Conf. Interval 
Number of RCTs -0.035 0.198 -0.089 0.018 -0.103 0.052 -0.206 0.001 
RCT duration of follow-up -0.004 0.196 -0.009 0.002 -0.009 0.011 -0.015 -0.002 
Use of active comparator in RCT -0.708 0.050 -1.415 -0.001 -0.897 0.022 -1.662 -0.131 
Clinical superiority demonstrated in RCT -0.523 0.111 -1.166 0.120 -0.352 0.323 -1.050 0.346 
Therapeutic Indication         
Central nervous system 0.882 0.319 -0.852 2.616 1.356 0.151 -0.493 3.205 
Malignancy/immunosuppression 
therapy 
0.906 0.295 -0.788 2.600 1.282 0.171 -0.553 3.117 
Respiratory system 1.415 0.302 -1.271 4.102 2.172 0.118 -0.554 4.899 
Cardiovascular disease 0.355 0.685 -1.359 2.070 0.453 0.638 -1.431 2.336 
Endocrine system 0.443 0.647 -1.453 2.339 0.263 0.802 -1.790 2.316 
Gastro-intestinal disorders 0.240 0.869 -2.615 3.095 2.001 0.141 -0.661 4.664 
Infections 0.363 0.678 -1.348 2.074 -0.063 0.949 -1.976 1.851 
musculoskeletal and joint diseases 0.348 0.721 -1.561 2.256 0.290 0.786 -1.806 2.386 
Nutrition and blood 0.224 0.835 -1.879 2.327 1.033 0.351 -1.137 3.204 
Skin 0.566 0.564 -1.358 2.490 -0.249 0.828 -2.498 1.999 
Size of eligible patient population -0.00000036 0.405 -0.0000012 0.0000005 -0.00000079 0.332 -0.0000024 0.0000008 
ICER 0.000025 0.011 0.0000057 0.0000448 0.000033 0.001 0.000013 0.000053 
Number of technologies appraised 
simultaneously 
0.648 0.001 0.277 1.018 0.466 0.074 -0.044 0.977 
National population size 0.00000094 0.087 -0.00000014 0.0000020 0.00000174 0.029 0.00000018 0.0000033 
SMC 46.499 0.083 -6.060 99.059 86.641 0.027 10.061 163.222 
Constant -51.408 0.083 -109.603 6.786 -95.335 0.027 -180.057 -10.613 
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Part 1. Description of HTA bodies included in the analysis 
NICE 
Established in 1999, the National Institute for Health and Care Excellence (NICE) is responsible for providing 
guidance to the National Health Service (NHS) in England and Wales on the funding of new technologies and their 
use, including pharmaceutical technologies (1,2). One of the key rationales for setting up NICE was to help tackle 
the geographic inequality in access to technology, or the phenomenon commonly referred to as ‘postcode 
prescribing’(3).  Since 2002, NICE's recommendations have been mandatory and NHS organizations have had to 
comply, usually within three months.  
The NICE HTA process involves a panel of clinical, academic, industry stakeholders and lay members (NICE 2008a).  
Appraisals by NICE are governed by the use of an established standard methodology for the evaluation of clinical 
and economic characteristics of a technology (4,5).  As outlined in its methods guide(5), a range of clinical criteria 
are evaluated during a NICE appraisal, with the consideration  of cost-utility evidence  an integral part of the 
process.  In addition to economic and clinical criteria, the patients’ (and carers’) perspective and patient (and 
carer) evidence, as well as submissions from other people working within the NHS, are taken into consideration via 
the consultation and stakeholder submission processes.  It should be added that NICE operates a process that 
emphasises the role of social values in decision-making (4), especially during appraisal of clinical effectiveness and 
cost-effectiveness evidence (2).  
SMC 
Established in 2001, the Scottish Medicines Consortium (SMC) advises NHS Scotland on the use of newly licensed 
technologies or newly licensed indications for existing technologies. The purpose of the SMC is “to avoid 
duplication of new medicines assessment by individual ADTCs [NHS Board Area Drugs and Therapeutics 
Committees], to avoid geographical inequity in decision making and to make the best use of expertise available 
across Scotland” (6) p. 4).  The composition of the Consortium and the New Drugs Committee (NDC) that advises 
the SMC on new technologies includes clinicians, pharmacists and health economists, in addition to stakeholders 
from manufacturers, patient groups and the government.  The SMC provides guidance to NHS Scotland based on a 
rapid review soon after the marketing authorisation is obtained for the technology (6,7). The assessment of the 
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SMC is based on evidence submitted by the manufacturer, and there is no third party assessment within its 
appraisal process (8).  A series of clinical and economic criteria are taken into account in the SMC’s assessment of 
pharmaceutical technologies (9).  Clinical effectiveness, relative to a comparator, is a key part of the SMC appraisal, 
which aims to assess the relevance of the efficacy and safety outcomes of the clinical studies to treatment practice 
and patients in Scotland.  The pharmaco-economic assessment examines the economic model and results 
submitted by the manufacturer, including its relevance and robustness.  Sensitivity analysis around the economic 
model results is an important component of the evaluation.  In addition to pharmaco-economic assessments, 
resource implications associated with the introduction of the technology are assessed by the SMC.  Submissions by 
patient groups are a formal part of the appraisal process.   
CVZ 
In the Netherlands, the College Voor Zorgverzekeringen (CVZ) has an important role in supporting and maintaining 
the quality, accessibility and affordability of health care through its HTA activities.  The Commissie Farmaceutische 
Hulp (CFH) is a part of the CVZ.  It is tasked with the assessment of the therapeutic value of new technologies for 
inclusion in the Medicine’s Reimbursement System (Geneesmiddelen Vergoedings Systeem – GVS), or inclusion in 
the various reimbursement policies of the Dutch Health Authority (Nederlandse Zorgautoriteit - NZa).  Collectively, 
the role of the CFH and CVZ is to provide advice to the Ministry of Health on the reimbursement list appropriate 
for the funding of each technology – the GVS 1A or 1B list, or specific reimbursement policies (e.g. the expensive 
drug list, or List ‘2’)(10-12).  The therapeutic value of the technology plays an important role in the CVZ 
recommendation (13).  The CVZ takes into account several factors, including the disease for which the technology 
is indicated and whether or not there is a standard of care already reimbursed for that system with the same 
indication, based on clinical guidelines and clinical criteria.  The review also collects information about the 
experience with the technology, such as time on the market, to assess the risk of unknown side effects occurring 
over time and to increase the certainty around the therapeutic benefit of the technology.   The financial 
implications of adoption of the technology are also assessed, similar to budget impact estimation.  The importance 
of each factor is weighted and technologies are compared, to come to a decision on the category of therapeutic 
benefit that should be applied (lower benefit, comparable benefit or higher benefit).  The CVZ also has a particular 
role, perhaps less common in other HTA bodies, of reviewing technologies for unlicensed indications, on the 
request of health insurance bodies.  In this situation, the CVZ is asked to establish if the unlicensed indication is 
rare (less than 1:150,000 population), if there is a scientific basis for the efficacy of the technology in this 
unlicensed indication and if there is no other alternative therapy available in the Netherlands for the condition 
under review.  Once the CVZ has provided its advice to the Ministry of Health, and the Ministry of Health gives its 
formal approval, the reimbursement decision for extramural  medicines is published on the Pharmaco-therapeutic 
Compass (Farmaco-therapeutisch Kompas)(10).   
HAS 
Since 2004, the Haute Autorité de Santé (HAS) in France has existed to reinforce the quality of treatment for the 
benefit of patients (14).  The role of the HAS is currently undergoing change and a new law was passed in October 
2012.  The description of the HAS and relevant committees below reflects the objectives and processes of the 
system during the period when this analysis was performed (2004-2009).  Through the Transparency Commission 
(Commission de la Transparence), it provides advice on the therapeutic value of technologies seeking 
reimbursement by the healthcare system.  The Transparency Commission includes 31 members (15) and is 
composed of physicians, pharmacists and specialists in epidemiology and research methods. There are several 
criteria upon which the appraisal is based(16).  The recommendations of the Commission, in 2004-2009, were 
based on an assessment of the medical service rendered by the technology (‘Service Medical Rendu’- SMR), by 
taking into consideration various factors including the severity of the disease, the efficacy and safety profile 
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demonstrated, and the importance of the management of this disease from a public health standpoint.  In 
addition, in 2004-2009, the Commission made a recommendation on the incremental medical service rendered 
(l’Amelioriation du Service Medical Rendu, -ASMR) defined by examining the efficacy and safety profile of the 
technology relative to a specified comparator.  There are five levels of ASMR as defined in the Commission’s 
regulations, ranging from ASMR I, which represents technologies that bring highly significant incremental medical 
value, to ASMR V, which represents technologies that show no incremental medical value.  The Commission also 
considers the target population for the technology and, for example, the nature of the technology in terms of its 
duration of treatment and dosing.  It is important to note that the cost of the technology is not considered during 
the appraisal process
3
 and the price is not known during the appraisal by the Transparency Commission.  The 
Commission’s conclusion is transmitted to the Comité Economique des Produits de Santé (CEPS).  This last 
committee is responsible for setting the price of medicines through negotiation with the manufacturers.  These 
negotiations are based on several components, although they are primarily driven by the ASMR rating which 
represents the incremental benefit of the technology compared to the standard of care. Additional factors taken 
into consideration in price negotiations include the size of the target population, the manufacturer’s research 
expenditure and advertising costs (11,17,18).    
 
                                                          
3
 In October 2012, a new law was passed (article 47 of the loi de financement de la sécurité sociale) which gives the 
HAS new competency in conducting medico-economic studies to evaluate health technologies. These medico-
economic studies may be conducted for a limited number of products to inform the Comité économique des 
produits de santé (CEPS) in their decision-making process. In addition, cost-effectiveness analyses may be 
conducted once the technology has been in the market and its price and real-life utilization are known, possibly 
jointly with post-reimbursement studies.   
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Part 2. Selection of Explanatory Variables 
Upon examination of the literature, three “streams” of research on factors impacting on HTA decision-
making became apparent.  Firstly, research on the impact of evidence on the HTA decision, which 
focuses on the degree to which evidence related to the medicine under review (whether clinical, 
economic or otherwise) can impact on HTA coverage decisions (19-23).  Secondly, research on the 
decision-making process itself, rather than on the technology (e.g. whether economic evaluation is a 
component of the decision-making process or not).  The literature examining the HTA appraisal process 
provides insights into a number of process-related factors that can potentially influence coverage 
decisions (23-26).  Thirdly, reference in the literature is made to the impact of the overall healthcare and 
welfare characteristics on HTA decision-making (e.g. the impact of healthcare expenditure levels and the 
health policy priorities being reinforced by the Ministry of Health at the time of HTA decision-making). 
The literature has shown that coverage decisions are influenced by macro factors, such as healthcare 
spending per capita, societal willingness to pay, the structure of the healthcare system, as well as ethical 
and social considerations (27-31).   Given these themes in the literature, it was hypothesised that HTA 
decisions were driven by the HTA decision-making process, the evidence considered within that process, 
and by the socio-economic and political context in which the decision was made (Fig. 1)  
 
Figure 1.   Health technology assessment (HTA) decision-making: hypothesised drivers 
 
 
 
 
Multinomial logistic regressions were used to assess the hypothesized influence of evidence, process 
and contextual variables on the different coverage outcomes from the HTA bodies (recommended, 
restricted or not recommended). The underlying relationship between the HTA outcomes and the 3 set 
of influential variables was thus modelled as: 
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𝐿𝑜𝑔 (
𝑃(𝑌 = 𝑗|𝐸𝐿 , 𝑃𝑀 , 𝐶𝑁)
1 − 𝑃(𝑌 = 𝑗|𝐸𝐿 , 𝑃𝑀 , 𝐶𝑁)
) =  𝛼𝑗 + ∑ 𝜀𝑗𝑙𝐸𝑙 + ∑ 𝜋𝑗𝑚𝑃𝑚 + ∑ 𝛾𝑗𝑛𝐶𝑛
𝑁
𝑛=1
𝑀
𝑚=1
𝐿
𝑙=1
 
 
Which results in: 
𝑃(𝑌 = 𝑗|𝐸𝐿 , 𝑃𝑀 , 𝐶𝑁) =
𝑒𝑋𝑗
1 + 𝑒𝑋𝑗
 
 
With 𝑋𝑗 = 𝛼𝑗 + ∑ 𝜀𝑗𝑙𝐸𝑙 + ∑ 𝜋𝑗𝑚𝑃𝑚 + ∑ 𝛾𝑗𝑛𝐶𝑛
𝑁
𝑛=1
𝑀
𝑚=1
𝐿
𝑙=1  
And where: 
 
𝑃(𝑌 = 𝑗|𝐸𝐿 , 𝑃𝑀 , 𝐶𝑁) is the probability of belonging to group j given 𝐸𝐿 , 𝑃𝑀 , 𝐶𝑁 
𝐸1, … , 𝐸𝐿  is the vector E of L explanatory EVIDENCE variables, 
𝑃1, … , 𝑃𝑀  is the vector P of M explanatory PROCESS variables, 
𝐶1, … , 𝐶𝑁  is the vector C of N explanatory CONTEXT variables, 
𝜀𝑗1, … , 𝜀𝑗𝐿  is the vector 𝜀 of the L coefficients corresponding to the L explanatory 
EVIDENCE variables 
𝜋𝑗1, … , 𝜋𝑗𝑀  is the vector 𝜋 of the M coefficients corresponding to M explanatory 
PROCESS variables 
𝛾𝑗1, … , 𝛾𝑗𝑁   is the vector 𝛾 of the N coefficients corresponding to N explanatory 
CONTEXT variables, 
𝛼𝑗   is the constant. 
 
Significant efforts were made to create a dataset that was consistent and comprehensive, and able to 
address the research questions.  It was a specific objective of this research to ensure that a 
comprehensive set of common variables was collected across the HTA bodies to avoid model 
misspecification.  From the general framework characterized by the equations presented above, overall 
research objectives and HTA-specific objectives were derived to reflect the understanding of the context 
and healthcare system within which each HTA body operates.  A common set of variables, 
complemented by HTA–specific variables where pertinent for the research objectives, were 
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subsequently selected to enable the measurement of the role of evidence, process and context in HTA 
decision-making, illustrated by EL , PM and CN above.
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Part 3. Standardising the Outcome Variable 
 
To conduct the analysis, it was necessary to standardise the way the outcome variable was defined.  Each agency 
has its own method for defining and thinking about HTA decisions.   
In order to be able to facilitate the analysis of the factors driving decision-making across HTA bodies, it was 
necessary to standardise the way the outcome variable was defined.  Each agency has its own method for defining 
and thinking about coverage decisions.  However, there are similarities in the types of coverage decisions made, 
which have been capitalised on to arrive at a series of ‘rules’ on how to define and classify coverage decisions by 
NICE, SMC, CVZ and HAS to allow for comparison and pooling (Table 1).    
 The analysis is based on using a three category outcome variable where the new technology can be:   
 recommended for routine use 
 recommended for restricted use 
or 
 not recommended 
 
HAS represents a specific challenge, in that the ASMR rating reflects the incremental value associated with a 
technology and impacts on the willingness of the healthcare system to approve increased funding for technologies 
that achieve high levels of ASMR (I or II) or restrict funding for those technologies with a low ASMR (V).  The ASMR 
does not represent the final funding decision; rather, a separate committee, the CEPS, has this responsibility as it is 
the entity responsible for finalising the price and volume agreements for technologies.  While recognising that the 
ASMR represents a different form of reimbursement decision than the coverage decisions made by SMC, NICE and 
CVZ, to allow for pooling a classification of ASMR ratings was adopted (described in Table A).  This was felt to be 
appropriate given that the price of the technology, and hence the funding of the technology, is primarily driven by 
the ASMR rating.  
Recommended technologies were defined as those technologies where full coverage was granted for the totality 
of the licensed population.  For NICE guidance, where a recommendation was made for a technology to be used in 
a population identical to its licensed indication, it was considered ‘recommended’.  For the CVZ, where the decision 
was to place the technology in the ‘basis paket’ (List 1A or 1B), or listed in the expensive drug list 
(Duregeneesmiddelen Beleidsregel) without any restriction or patient co-payment, the technology was considered 
to be recommended
4
.  In France, the ASMR was used to classify outcomes.  Recommended technologies in this 
                                                          
4
 It should be noted that category 1A within the Dutch decision-making process presented some ambiguity in terms 
of where it should be considered within this analysis.  This is because while for products listed in 1A there is a price 
pre-defined based on already existing reference products,  it is the manufacturer who in principle proposes in 
which list (1A or 1B) they would like to submit their technology, according to the therapeutic differentiation of the 
product –thus the manufacturer submits a proposal with a price in the anticipated range, and it is not the CVZ who 
asks for a price reduction to meet the reference price rule as a result of the appraisal but rather a position taken by 
the manufacturer at the start of the appraisal process.  In addition, both 1A and 1B result in similar coverage from 
the patient perspective.  This is why we decided to consider both 1A and 1B listings recommendations by the CVZ. 
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analysis were considered to be those with an ASMR I- II, representing technologies with important incremental 
medical value relative to standard of care.     
 
Restricted technologies were defined as those technologies where coverage was granted for a sub-population of 
the licensed indication and/or with restrictions in terms of acquisition cost or utilization (e.g. monitoring or 
specialist use required) (Raftery 2006).  For NICE and the SMC, a coverage decision was considered to be a 
restriction if it was recommended for use in a sub-population of its licensed indication; in a second line or higher 
line of therapy; required monitoring, recommended upon it bearing the lowest acquisition cost or prescription by a 
specialist. For the CVZ, where the decision was to place the technology in the ‘basis paket’, but only for use in a 
sub-population or with a patient co-payment, this technology was considered as restricted.  With regard to HAS, 
technologies with ASMR III-IV representing modest or minor medical value are associated with lower price levels 
(and hence funding) than technologies with ASMR I-II.  These were considered to be restricted technologies.  
 
Not recommended technologies were those for which no coverage was granted.  A medication was considered to 
be not recommended for use by NICE or SMC guidance if the words “not recommended” were stated in the 
guidance/report.   Within CVZ decisions, the technology was considered to be not recommended when it was 
stated to be not recommended in the CVZ ‘advies’ statement and was not included in any reimbursement list.  
With regard to HAS, technologies with an ASMR V offer no incremental benefit versus the comparators, and as per 
legislation cannot be included on the reimbursement list.  An ASMR V was therefore considered to be ‘not 
recommended’.   It should be noted however, that for HAS, technologies with an ASMR V can obtain 
reimbursement from the healthcare system, but only if associated with cost-savings.  This is different from the CVZ 
where technologies not recommended for funding are excluded from the reimbursement list.  Other research 
conducted on the ASMR has made a similar assumption whereby technologies with ASMR V were considered to 
represent non-recommendation (33).  While for the purposes of this analysis it was felt appropriate to consider 
ASMR V as a non-recommendation, it is important to bear in mind that the implications of an ASMR V may not be 
the same as the implications of non recommendation from the SMC or NICE, for example.   
While recognising that the ASMR represents a different form of HTA decision than the decisions made by SMC, 
NICE and CVZ, given that the price of the technology – and hence the funding of the technology – is primarily 
driven by the ASMR rating, it was considered appropriate to pursue a multi-HTA analysis by classifying HTA 
decisions by NICE, SMC, CVZ and HAS (Table 1).    
Table 1 Classification of HTA decisions into a 3-category outcome variable:  definitions per HTA body 
HTA body Recommended Restricted Not Recommended 
NICE Full HTA was granted for the 
totality of the licensed 
population  
A sub-population of the licensed 
indication and/or with 
restrictions in terms of 
acquisition cost or utilization 
(e.g. monitoring or specialist use 
required) 
“Not recommended” stated in 
section 1 of guidance 
SMC If word “recommended” used in 
summary statement 
If word “restricted” was used in 
summary statement 
If words “not recommended” 
were used in summary 
statement 
CVZ If technology was placed in If technology placed in list 2, or If the technology was not 
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reimbursement lists 1A or 1B, or 
the expensive drug list 
if patient co-payment is 
necessary to access medication 
included in any reimbursement 
list 
HAS ASMR I-II ASMR III-IV ASMR V 
 
 
ASMR = l’Amelioriation du Service Medical Rendu rating; CVZ = College voor Zorgverzekeringen;  HAS = 
Haute Autorité de Santé; HTA= Health Technology Assessment;  NICE=National Institute for Health and 
Care Excellence; SMC=Scottish Medicines Consortium
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Part 4. List of Common Set of Technologies Appraised by All Four HTA bodies 
 
Drugs reviewed by all 4 bodies NICE SMC CVZ HAS Total # of 
Reviews 
abatacept 1 1 1 1 4 
adalimumab 1 4 7 6 18 
bevacizumab 1 3 2 5 11 
bortezomib 1 2 3 4 10 
cetuximab 1 3 2 2 8 
cinacalcet 1 2 1 2 6 
clopidogrel 1 2 4 1 8 
dabigatran 1 1 1 1 4 
entecavir 1 1 1 1 4 
etanercept 1 2 5 7 15 
infliximab 1 3 4 4 12 
lenalidomide 1 1 1 1 4 
levetiracetam 1 2 2 1 6 
memantine 1 1 2 1 5 
natalizumab 1 2 1 1 5 
pegaptanib 1 1 1 2 5 
pemetrexed 1 5 2 3 11 
rituximab 1 5 3 4 13 
rivaroxaban 1 1 2 1 5 
sunitinib 1 3 3 3 10 
tacrolimus 1 1 1 3 6 
telbivudine 1 1 1 1 4 
teriparatide 1 1 1 4 7 
topotecan 1 2 1 2 6 
trastuzumab 1 1 1 2 5 
Total appraisals     192 
 
CVZ = College voor Zorgverzekeringen;  HAS = Haute Autorité de Santé; HTA= Health Technology 
Assessment;  NICE=National Institute for Health and Care Excellence; SMC=Scottish Medicines 
Consortium
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Part 5. SUPPLEMENTARY TABLE 
 
Table 2 Descriptive statistics - comparison of four HTA bodies included in multi-HTA analysis 
  NICE  (n=118) SMC  (n=288) CVZ  (n=256) HAS (n=315) P 
value 
Test  
  mean (95% CI) mean (95% CI) mean (95% CI) mean (95% CI)   
NoRCT 6.7 (5.2,8.4) 2.2 (1.9,2.5) 2.6 (2.3,3) 2.3 (2.1,2.6) <0.01 1 
RCTsize 1249 (807,1691) 991 (689,1294) 830 (494,1165) 1154 (824,1484) <0.01 3 
RCTsignificant- yes 39% (29%,47%) 58% (48%,60%) 20% (33%,45%) 47% (33%,43%) <0.01 2 
No 16% (9%,22%) 19% (13%,22%) 46% (13%,22%) 20% (12%,20%) <0.01 2 
Inconsistent 45% (34%,52%) 23% (16%,26%) 34% (23%,34%) 33% (21%,31%) NS 2 
RCTduration 76.2 (63.5,88.9) 4490% (3840%,5140%) 3950% (3340%,4560%) 4930% (4120%,5740%) <0.01 1 
RCTcomparator 47% (39%,55%) 52% (46%,57%) 44% (38%,51%) 42% (37%,48%) <0.01 3 
ObsStudies 0.6 (0.1,1.1) 1.3 (-0.4,2.9) 0.6 (0.4,0.7) 0.3 (0.2,0.4) <0.01 1 
CUA 95% (91%,99%) 74% (69%,79%) 11% (7%,15%) 0% (0%,0%) <0.01 2 
ICER £31,266 (£29,122,£42,410) £34,055 
(£21,630,£46,481) 
£30,977 (£8,643,£53,312)  - <0.01 3 
MultipleCEA 63% (54%,72%) 1% (0%,2%) 1% (0%,2%)  - <0.01 1 
MultipleICERs – low 
range 
£13,260 (£10,409,£16,110) £10,399 (-
£9,782,£30,580) 
£85,091 (-
£198,747,£368,928) 
 - <0.10 3 
MultipleICERs – low 
range 
£107,421 (£66,886,£147,956) £18,207 (-
£2,672,£39,086) 
£221,499 
(£201,610,£241,389) 
 - <0.05 3 
univariateICER – low 
value 
0.43 (0.34,0.52) 0.57 (0.42,0.73) 0.66 (0.42,0.9)  - <0.10 3 
univariateICER –high 
value 
£25,417 (£6,412,£44,422) £33,277 (£8,916,£57,637) £15,187 (£4,338,£26,036)  - <0.05 3 
probabilisticICER £167,389 (£56,865,£277,913) £77,927 
(£19,847,£43,448) 
£92,826 (-
£6,356,£192,008) 
 - <0.01 3 
NonCUA 23% (15%,30%) 30% (25%,36%) 15% (11%,20%)  - <0.01 2 
BudgetImp £701.3 (£179.7,£1,223.0) £1.2 (£0.9,£1.5) £31.0 (£5.9,£56.2)  -     
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Eligiblepop 2,418,119 
(1,256,514,3,579,724) 
11,277 (1,647,20,908) 94,543 (31,394,157,693) 511,047 
(314,122,707,972) 
<0.01 1 
AlternativeTx 89% (83%,95%) 83% (79%,88%) 79% (74%,84%) 89% (85%,92%) <0.01 2 
PatientSub 0.87 (0.81,0.93) 0.42 (0.36,0.48) 0.04 (0.02,0.06) 0 (0%,0%) <0.01 2 
NoDecMakers 30 (28,32) 25 (24,25) 20 (20,20) 31 (31,31) <0.01 1 
CEAprocess 100% (100%,100%) 100% (100%,100%) 67% (61%,73%) 0% (0%,0%) <0.01 2 
BudgetImpProcess 100% (100%,100%) 100% (100%,100%) 100% (100%,100%) 0% (0%,0%) <0.01 2 
Price  100% (100%,100%) 100% (100%,100%) 100% (100%,100%) 0% (0%,0%) <0.01 2 
NoTech 2.8 (2.5,3.1) 1 (1,1) 1 (1,1) 1 (1,1) <0.01 1 
Accountability  0% (0%,0%) 0% (0%,0%) 0% (%,0%) 0% (0%,0%) n/a 2 
Independence  100% (100%,100%) 0% (0%,0^%) 100% (100%,100%) 100% (100%,100%) <0.01 2 
Date  2007(2006,2007) 2006(2006,2006) 2006(2006,2006) 2007(2006,2007) <0.01 1 
PopulationSize 
(million)  
53.9(53.8,54) 5.13(5.12,5.13) 16.3(16.3,16.4) 63.4(63.3,63.5) <0.01 3 
healthcareGDP 8% (8%,8%) 8% (8%,8%) 10% (10%,10%) 11% (11%,11%) <0.01 1 
HealthExp £175(£173,£176) £190(£189,£190) £249(£246,£251) £439(£437,£441) <0.01 3 
Election 7% (2%,11%) 40% (35%,45%) 20% (15%,24%) 30% (25%,36%) <0.01 2 
Priority  56% (47%,65%) 66% (61%,71%) 55% (49%,61%) 70% (65%,75%) <0.01 2 
OrphanDesig  3% (0%,5%) 11% (8%,15%) 9% (5%,12%) 9% (6%,12%) <0.05 2 
Cardiovascular system 10% (5%,16%) 11% (7%,14%) 9% (5%,12%) 14% (10%,18%) NS 2 
Central nervous system 15% (9%,22%) 22% (16%,26%) 16% (12%,21%) 18% (14%,23%) NS 2 
Ear, nose and 
oropharynx 
0% (0%,0%) 0% (0%,1%) 1% (0%,2%) 0% (0%,1%) NS 2 
Endocrine system 1% (-1%,3%) 9% (5%,12%) 6% (3%,9%) 6% (4%,9%) <0.05 2 
Eye 2% (-1%,4%) 1% (0%,2%) 2% (0%,3%) 2% (0%,3%) NS 2 
Gastro-intestinal 
system 
2% (-1%,4%) 4% (2%,6%) 5% (2%,7%) 3% (1%,6%) NS 2 
Infections 12% (6%,18%) 10% (7%,14%) 9% (5%,12%) 12% (8%,15%) NS 2 
Malignant disease and 
immunosuppression 
31% (22%,39%) 23% (20%,30%) 25% (19%,30%) 24% (19%,29%) NS 2 
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Musculoskeletal and 
joint diseases 
19% (12%,27%) 3% (1%,6%) 10% (6%,14%) 9% (6%,12%) <0.01 2 
Nutrition and blood 3% (0%,5%) 6% (3%,9%) 7% (4%,10%) 3% (1%,6%) NS 2 
Obstetrics, 
gynaecology, and 
urinary-tract disorders 
0% (0%,0%) 2% (0%,3%) 3% (1%,5%) 0% (0%,1%) <0.05 2 
Respiratory system 1% (-1%,3%) 3% (2%,6%) 4% (1%,6%) 2% (1%,4%) NS 2 
Skin 5% (0.01,0.09) 3% (2%,6%) 5% (2%,7%) 4% (2%,7%) NS 2 
 
CEA=Cost Effectiveness Analysis;  CUA= Cost Utility Analysis;  CVZ = College voor Zorgverzekeringen;  GDP=gross domestic product;  HAS = Haute 
Autorité de Santé; HTA= Health Technology Assessment;  ICER Incremental Cost-effectiveness Ratio; NICE=National Institute for Health and Care 
Excellence; QALY =Quality-Adjusted Life-Year; RCT=Randomised Controlled Trial;  SMC=Scottish Medicines Consortium; TAR = Technical 
Appraisal Report. 
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